Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Having supplied HIV treatment regimens to more than 8m patients worldwide in 2017, Mylan NV now is turning its attention to the US with a pair of single-tablet combination regimens recently approved by the US FDA. It seems likely that the generics titan will focus mainly on Medicaid and other economically disadvantaged patient groups with a strategy of pricing its regimens below what competitors like Gilead Sciences Inc. and ViiV Healthcare are charging for their combination pills.

Mylan announced on March 2 that it will launch the three-drug combo Symfi Lo in the coming weeks, with two-drug...